



**PRESS RELEASE**

## **AMOÉBA announces that the dossier for its biocidal active substance approval is still under scientific review by the US EPA**

**Lyon (France), March 28<sup>th</sup>, 2019 - AMOÉBA (FR0011051598 - AMEBA)**, producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, announces that the dossier for its biocidal active substance approval is still under scientific review by the US Environmental Protection Agency (EPA).

As a reminder, the registration of the biocidal active substance *Willaertia magna C2c Maky* and the biocidal product BIOMEBA in the United States is in its final phase of evaluation ('last science review', see Press Release dated 12 September 2018). The company expected that the recent government shutdown (see Press Release dated 1 February 2019) could have an impact on the EPA's decision date, scheduled for the first quarter of 2019.

The EPA has just informed the Company that the scientific review is still ongoing and that, once the scientific review is completed, the EPA will inform the Company on how EPA will move forward with the application for the approval of the biocidal active substance *Willaertia magna C2c Maky* and the biocidal product BIOMEBA.

However, the EPA cannot provide a deadline until the scientific review is completed.

As soon as the timetable is specified or the EPA's decision known, Amoéba will provide this information by way of a press release.



### **About AMOÉBA:**

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn <sup>(1)</sup> on a global chemical biocide market for water treatment, evaluated at €21Bn <sup>(2)</sup> and on the biocontrol market for plant protection estimated globally at €1.6Bn <sup>(4)</sup>. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million <sup>(3)</sup> in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-biocide.com](http://www.amoeba-biocide.com).



(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

## **Contacts :**

### **Amoéba**

Valérie FILIATRE

Directeur administratif et Financier

04 26 69 16 00

valerie.filiatre@amoeba-biocide.com

### **Actifin**

Ghislaine GASPARETTO

Communication financière

01 56 88 11 11

ggasparetto@actifin.fr

## **Disclaimer**

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 27, 2018 (a copy of which is available on [www.amoeba-biocide.com](http://www.amoeba-biocide.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.